Mauro Perretti

Professor Mauro Perretti is a leading academic in Immunopharmacology at Queen Mary University of London’s William Harvey Research Institute (WHRI), part of the Faculty of Medicine and Dentistry. He holds a Doctorate from the University of London (1996) and has held senior roles including Deputy Director (2006–2013), Co-Director (2013–2016), and Dean for Research (2015–2022) at WHRI.

His research focuses on resolving inflammation, particularly in arthritis and sepsis, with emphasis on neutrophil biology, extracellular vesicles, and pro-resolving mediators like resolvins and Annexin A1. Collaborations include SynAct Pharma and BioAegis Therapeutics to advance resolution pharmacology. He leads a team of post-doctoral fellows and PhD students investigating therapeutic strategies targeting inflammation resolution.

Prof Perretti’s work spans clinical and preclinical studies, including phase trials for pro-resolving drugs in COVID-19 and arthritis. He has secured funding from MRC, Barts Charity, and commercial partners. His teaching includes lectures on receptor theory and inflammation resolution for undergraduate and postgraduate students.

• Education:
  • BSc Medicinal Chemistry, University of Florence (1985)
  • MSc Pharmacology & Toxicology, University of Florence (1988)
  • PhD, University of London (1996)
• Key Collaborations:
  • Dr. Dianne Cooper (QMUL)
  • Prof. Jesmond Dalli (QMUL)
  • External partners: University College Dublin, University of Sao Paulo
• Grants & Sponsors:
  • Medical Research Council
  • Barts Charity
  • Chernajovsky Foundation
• Labs & Teams:
  • Focus on resolution pharmacology and neutrophil-driven therapies
  • Active partnerships with SynAct Pharma and ResoTher Pharma